APTN
What one share of Adaptin Bio holds
Biological Products, (No Diagnostic Substances)
We are a biopharmaceutical company pioneering a transformational approach to enhance the transfer of therapeutics into the brain, facilitating the treatment of brain cancers and other unmet medical conditions. The Company’s proprietary technology harnesses the human immune system’s ability to target, recognize, destroy or deliver therapeutics to specific cells, including cancer cells.
Adaptin Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.63 |
|---|---|
| Cash and investments | $0.07 |
| Book value | −$0.18 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$0.02 | — | −$0.02 | — | −$0.20 |
| 2024 | — | −$0.96 | — | −$0.20 | — | −$1.26 |
| 2025 | — | −$0.66 | — | −$0.61 | — | −$0.17 |